Therapy Areas
Latest News
Trodelvy plus Keytruda shows significant progression-free survival benefit in first-line PD-L1+ metastatic triple-negative breast cancer
21 April 2025 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) on Monday reported positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 trial evaluating Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembro...
ENHERTU plus pertuzumab shows significant improvement over standard care in HER2 positive metastatic breast cancer
21 April 2025 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) on Monday reported positive topline results from the DESTINY-Breast09 phase 3 ...
Akeso's Ebdarokimab approved in China for moderate-to-severe plaque psoriasis
21 April 2025 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Friday that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from China's National Medical Products A...
Ymmunobio's YB-800 ADCs achieve proof of concept in preclinical in vitro and in vivo Tests
21 April 2025 - Switzerland-based Ymmunobio AG (YB), which focuses on the development of new cancer therapeutics, announced on Friday that its two-antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed preclinical proof of co...
SparX to present Phase 1 clinical update during AACR 2025
21 April 2025 - Development-stage biopharmaceutical company SparX Biopharmaceutical Corp announced on Friday that it will present a clinical update on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-i...
Sol-Gel Technologies sells US rights to EPSOLAY and TWYNEO to Mayne Pharma for USD16m
17 April 2025 - Dermatology company Sol-Gel Technologies Ltd (NASDAQ:SLGL) revealed on Thursday that it has entered into a product purchase agreement with a subsidiary of Mayne Pharma Group Limited (ASX:MYX) for the sale and exclusive license of the ...
Hoth Therapeutics secures Japanese patent for RNA-based therapy targeting KIT gene
17 April 2025 - Biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) announced on Thursday that it has been granted a key patent by the Japan Patent Office, expanding its global intellectual property portfolio in RNA-based precision oncology...